ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

STEGLATRO
Diabetes
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

STEGLATRO Rx

Generic Name and Formulations:
Ertugliflozin 5mg, 15mg; tabs.

Company:
Merck & Co., Inc.

Therapeutic Use:

RECENT UPDATES

Monograph added.

Indications for STEGLATRO:

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations Of use:

Not for treating type 1 diabetes mellitus or diabetic ketoacidosis.

Adult:

Take in the AM. Initially 5mg once daily; if tolerated and need additional glycemic control; may increase to max 15mg once daily. Renal impairment: if eGFR 30–<60mL/min/1.73m2: do not initiate; if persistently between 30–<60mL/min/1.73m2: continued use is not recommended.

Children:

<18yrs: not established.

Contraindications:

Severe renal impairment (eGFR <30mL/min/1.73m2), ESRD, or on dialysis.

Warnings/Precautions:

Correct volume depletion before initiating. Monitor for signs/symptoms of hypotension (esp. elderly, patients with renal impairment, low systolic BP, or on diuretics). Assess for ketoacidosis in presence of signs/symptoms of metabolic acidosis, regardless of blood glucose levels; discontinue if suspected, evaluate and treat; consider risk factors before initiation (eg, pancreatic insulin deficiency, caloric restriction, alcohol abuse). Evaluate renal function prior to starting and monitor periodically thereafter. Risk of acute kidney injury in hypovolemia, chronic renal insufficiency, CHF, and concomitant drugs (eg, diuretics, ACEIs, ARBs, NSAIDs). Consider temporarily discontinuing in reduced oral intake or fluid losses; monitor for acute kidney injury; discontinue and treat if occurs. Increased risk of genital mycotic infections or UTIs; monitor and treat if occurs. History of prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers. Monitor for sign/symptoms of infection (including osteomyelitis), new pain/tenderness, sores or ulcers involving the lower limbs; discontinue if occur. Monitor for increases in LDL-C; treat if occur. Severe hepatic impairment: not recommended. Elderly. Pregnancy (2nd & 3rd trimesters), nursing mothers: not recommended.

Interactions:

Consider a lower dose of concomitant insulin/insulin secretagogue to reduce risk of hypoglycemia. Hypotension with concomitant diuretics. May cause false (+) urine glucose tests or unreliable measurements of 1,5-AG assay; use alternative methods to monitor glycemic control.

Pharmacological Class:

Sodium-glucose co-transporter 2 (SGLT2) inhibitor.

Adverse Reactions:

Female genital mycotic infections, UTIs, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decrease, thirst; volume depletion, renal impairment, ketoacidosis, amputation, hypoglycemia, urosepsis, pyelonephritis.

Generic Availability:

NO

How Supplied:

Tabs—30, 90, 500

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs